参考文献/References:
[1]Virani SS,Alonso A,Aparicio HJ,et al. Heart disease and stroke statistics2021 update:a report from the American Heart Association[J]. Circulation,2021,143(8): e254-e743.
[2]Nordestgaard BG,Benn M,Schnohr P,et al. Nonfasting triglycerides and risk of myocardial infarction,ischemic heart disease,and death in men and women[J]. JAMA,2007,298(3):299-308.
[3]Lütjohann D,Kl?r HU,Stellaard F. Measurement of serum low density lipoprotein cholesterol and triglyceride-rich remnant cholesterol as independent predictors of atherosclerotic cardiovascular disease:possibilities and limitations[J]. Nutrients,2023,15(9):2202.
[4]Szili-Torok T,Tietge UJF. Remnant cholesterol is just another word for triglycerides when calculating LDL-C using the friedewald formula[J]. J Am Coll Cardiol,2021,77(14):1841.
[5]Azimi V,Farnsworth CW,Roper SM. Comparison of the Friedewald equation with Martin and Sampson equations for estimating LDL cholesterol in hypertriglyceridemic adults[J]. Clin Biochem,2022,108:1-4.
[6]Varbo A,Nordestgaard BG. Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction[J]. Eur Heart J,2021,42(47):4833-4843.
[7]Quispe R,Martin SS,Michos ED,et al. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB:a primary prevention study[J]. Eur Heart J,2021,42(42):4324-4332.
[8]Wadstr?m BN,Pedersen KM,Wulff AB,et al. Elevated remnant cholesterol and atherosclerotic cardiovascular disease in diabetes:a population-based prospective cohort study[J]. Diabetologia,2023,66(12):2238-2249.
[9]Nordestgaard BG,Langsted A,Mora S,et al. Fasting is not routinely required for determination of a lipid profile:clinical and laboratory implications including flagging at desirable concentration cut-points—A joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine[J]. Eur Heart J,2016,37(25):1944-1958.
[10]Fu L,Tai S,Sun J,et al. Remnant cholesterol and its visit-to-visit variability predict cardiovascular outcomes in patients with type 2 diabetes:findings from the ACCORD cohort[J]. Diabetes Care,2022,45(9):2136-2143.
[11]Casta?er O,Pintó X,Subirana I,et al. Remnant cholesterol,not LDL cholesterol,is associated with incident cardiovascular disease[J]. J Am Coll Cardiol,2020,76(23):2712-2724.
[12] Ministrini S,Carbone F,Montecucco F. Updating concepts on atherosclerotic inflammation:from pathophysiology to treatment[J]. Eur J Clin Invest,2021,51(5):e13467.
[13] Liberale L,Montecucco F,Schwarz L,et al. Inflammation and cardiovascular diseases:lessons from seminal clinical trials[J]. Cardiovasc Res,2021,117(2):411-422.
[14]Varbo A,Benn M,Tybj?rg-Hansen A,et al. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease,whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation[J]. Circulation,2013,128(12):1298-1309.
[15]Ohmura H. Contribution of Remnant Cholesterol to Coronary Atherosclerosis[J]. J Atheroscler Thromb,2022,29(12):1706-1708.
[16]Saeed A,Feofanova EV,Yu B,et al. Remnant-like particle cholesterol,low-density lipoprotein triglycerides,and incident cardiovascular disease[J]. J Am Coll Cardiol,2018,72(2):156-169.
[17]Wang L,Gill R,Pedersen TL,et al. Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation[J]. J Lipid Res,2009,50(2):204-213.
[18]Xu J,Qu P,Du X,et al. Change in postprandial level of remnant cholesterol after a daily breakfast in chinese patients with hypertension[J]. Front Cardiovasc Med,2021,8:685385.
[19]Lozhkin A,Vendrov AE,Pan H,et al. NADPH oxidase 4 regulates vascular inflammation in aging and atherosclerosis[J]. J Mol Cell Cardiol,2017,102:10-21.
[20] Alloza I,Salegi A,Mena J,et al. BIRC6 is associated with vulnerability of carotid atherosclerotic plaque[J]. Int J Mol Sci,2020,21(24):9387.
[21]Murgia A,Erta M,Suri JS,et al. CT imaging features of carotid artery plaque vulnerability[J]. Ann Transl Med,2020,8(19) :1261.
[22]Aneni EC,Osondu CU,de la Cruz J,et al. Lipoprotein sub-fractions by ion-mobility analysis and its association with subclinical coronary atherosclerosis in high-risk individuals[J]. J Atheroscler Thromb,2019,26(1):50-63.
[23]Hao QY,Gao JW,Yuan ZM,et al. Remnant cholesterol and the risk of coronary artery calcium progression:insights from the CARDIA and MESA Study[J]. Circ Cardiovasc Imaging,2022,15(7):e014116.
[24]沈雪阳何亚玲葛朝明. 残余胆固醇在急性缺血性卒中发病中的作用及其机制研究进展[J]. 山东医药,2022,62(6):107-110.
[25]Gabani MShapiro MD,Toth PP. The role of triglyceride-rich lipoproteins and their remnants in atherosclerotic cardiovascular disease[J].Eur Cardiol,2023,18:e56.
[26]Li H,Miao S,Chen L,et al. Association and mediating mechanism between remnant cholesterol and first-ever stroke among the Chinese general population[J]. Front Neurosci,2023,17:1161367.
[27]Hajduch E,Lachkar F,Ferré P,et al. Roles of ceramides in non-alcoholic fatty liver disease[J]. J Clin Med,2021,10(4):792.
[28]Bandet CL,Tan-Chen S,Bourron O,et al. Sphingolipid metabolism:new insight into ceramide-induced lipotoxicity in muscle cells[J]. Int J Mol Sci,2019,20(3):479.
[29]Li M,Chi X,Wang Y,et al. Trends in insulin resistance:insights into mechanisms and therapeutic strategy[J]. Signal Transduct Target Ther,2022,7(1):216.
[30]Vallejo-Vaz AJ,Fayyad R,Boekholdt SM,et al. Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial[J]. Circulation,2018,138(8):770-781.
[31]Tsunoda F,Asztalos IB,Horvath KV,et al. Fenofibrate,HDL,and cardiovascular disease in Type-2 diabetes:the DAIS trial[J]. Atherosclerosis,2016,247:35-39.
[32]Das Pradhan A,Glynn RJ,Fruchart JC,et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk[J]. N Engl J Med,2022,387(21):1923-1934.
[33]Toth PP,Hamon SC,Jones SR,et al. Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method:analysis of 3 randomized trials versus placebo[J]. Lipids Health Dis,2016,15:28.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(8):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]李乐亮,综述,李萍,等.炎症标志物与颈动脉粥样斑块的稳定性[J].心血管病学进展,2016,(3):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
LI Leliang,LI Ping.Stability of Inflammatory Markers and Carotid Artery Plaque[J].Advances in Cardiovascular Diseases,2016,(8):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
[3]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(8):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[4]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(8):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[5]乐健 何胜虎.前蛋白转化酶枯草溶菌素9致动脉粥样硬化的机制研究进展[J].心血管病学进展,2019,(7):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
YUE Jian,HE Shenghu.Advances in the mechanism of PCSK9-induced atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(8):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
[6]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(8):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[7]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(8):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[8]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(8):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[9]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(8):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[10]武亚琳,梁斌,杨志明.NLRP3/IL-1β途径的促动脉粥样硬化作用及临床应用[J].心血管病学进展,2019,(6):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
WU Yalin,LIANG Bin,YANG Zhiming.The Role of NLRP3/IL-1in Atherosclerosis and Clinical Application[J].Advances in Cardiovascular Diseases,2019,(8):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
[11]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(8):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[12]邹先明 赵然尊.长链非编码RNA ANRIL与心血管疾病的研究进展[J].心血管病学进展,2020,(2):167.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.017]
ZOU Xianming,ZHAO Ranzun.Long Non-Coding RNA ANRIL and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(8):167.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.017]
[13]毕一鸣 曹丰.内皮细胞功能异常与动脉粥样硬化的研究进展[J].心血管病学进展,2022,(2):150.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.014]
BI YimingCAO Feng.Vascular Endothelial Cells Involved?n the Pathophysiological Process of Atherosclerosis[J].Advances in Cardiovascular Diseases,2022,(8):150.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.014]
[14]董博华 吴雨晴 扈家源 魏宇涵 张桂彬 赵亚楠 陈喆 杨文琦.细颗粒物暴露对急性冠脉综合征作用机制的研究进展[J].心血管病学进展,2023,(2):132.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.008]
DONG Bohua,WU Yuqing,HU Jiayuan,et al.Research Progress on the Mechanism of PM2.5 Exposure on Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2023,(8):132.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.008]
[15]刘张弛 杨波.瞬时受体电位香草酸亚型4在心血管疾病中的研究进展[J].心血管病学进展,2023,(9):777.[doi:10.16806/j.cnki.issn.1004-3934.2023.09.000]
LIU Zhangchi,YANG Bo?/html>.Transient Receptor Potential Vanilloid 4 in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2023,(8):777.[doi:10.16806/j.cnki.issn.1004-3934.2023.09.000]
[16]龙雪蛟 洪绍彩 贝俊杰.血小板参数在心血管疾病中的研究进展[J].心血管病学进展,2023,(10):945.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.018]
LONG Xuejiao,HONG Shaocai,BEI Junjie.Progress of Platelet Parameters in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2023,(8):945.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.018]
[17]康雅隆 齐鸿飞 葛腾 彭涛 余婷 剧嘉欣 程草草 关芳 余湖斌 王海芳.小干扰RNA降脂药物英克司兰在心血管疾病中的研究进展[J].心血管病学进展,2024,(6):529.[doi:10.16806/j.cnki.issn.1004-3934.2024.06.012]
KANG Yalong,QI Hongfei,GE Teng,et al.siRNA Lipid-Lowering Drug Inclisiran in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2024,(8):529.[doi:10.16806/j.cnki.issn.1004-3934.2024.06.012]
[18]黄佳宇 熊安琪 蒋弼瀛 陈文佳.液-液相分离在心血管疾病中的研究进展[J].心血管病学进展,2024,(7):603.[doi:10.16806/j.cnki.issn.1004-3934.2024.07.007]
HUANG Jiayu,XIONG Anqi,JIANG Biying,et al.Liquid-Liquid Phase Separation in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2024,(8):603.[doi:10.16806/j.cnki.issn.1004-3934.2024.07.007]
[19]丁芳芳 廖付军 鲍海龙 李洁琪.非高密度脂蛋白胆固醇与动脉粥样硬化性心血管疾病关系的研究进展[J].心血管病学进展,2024,(9):806.[doi:10.16806/j.cnki.issn.1004-3934.2024.09.009]
DING Fangfang,LIAO Fujun,BAO Hailong,et al.The Relationship Between Non-High-Density Lipoprotein Cholesterol and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2024,(8):806.[doi:10.16806/j.cnki.issn.1004-3934.2024.09.009]